RXRX logo

RXRX

Profile

Full Name

Recursion Pharmaceuticals, Inc.

Ticker Symbol

RXRX

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

April 16, 2021

Indexes

Not included

Website

http://www.recursion.com

Employees

800

Key Details

Price

$5.03(-6.85%)

Market cap

$2.04B(Mid cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$58.49M(+33.30% YoY)

Annual EPS

-$1.69(-6.96% YoY)

PE ratio

-

Next earnings date

Aug 8, 2025

Next ex-dividend date

N/A

Next split date

N/A

Quick Search

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    See Full Chart & Historical Data

    Analyst ratings

    Price

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Current Price

    $5.03
    RXRX price is $5.03

    30-Day Relative Volume

    1.69
    RXRX 30-day relative volume is 1.69

    Price Performance

    Price Most recent change

    -6.85%
    RXRX price was down -6.85% on Jun 27, 2025

    Price YTD change

    -25.59%
    RXRX price is down -25.59% since January 1st

    Price 1-year change

    -33.6%
    RXRX price is down -33.6% year-on-year

    Price 3-year change

    -39.03%
    RXRX price is down -39.03% over the past 3 years

    Price Range

    Price All-time high

    $42.81
    RXRX price is currently -88.25% below its historical high of $42.81

    Price 3-year low

    $3.79
    RXRX price is currently +32.72% above its 3-year low

    Capitalization

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Market cap

    Market cap

    $2.04B
    RXRX market capitalization is $2.04 billion

    Market cap 3-year change

    +44.09%
    RXRX market capitalization is up +44.09% over the past 3 years

    Market cap All-time high

    $6.96B
    RXRX market capitalization is currently -70.63% below its historical high of $6.96 billion

    Market cap sector rank

    83.14%
    RXRX market capitalization is higher than 83.14% of companies in Healthcare sector

    Shares Outstanding

    Shares Outstanding 1-Year Change

    +71.04%
    RXRX shares outstanding is up +71.04% year-on-year

    Shares Outstanding 3-Year Change

    +136.32%
    RXRX shares outstanding is up +136.32% over the past 3 years

    Technical Indicators

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Beta

    2.50
    RXRX beta is 2.50

    200-day SMA

    $6.34
    RXRX price is currently -20.68% below its 200-day simple moving average

    50-day SMA

    $4.92
    RXRX price is currently +2.31% above its 50-day simple moving average

    RSI

    50.94
    RXRX 14-day relative strength index is 50.94

    Volume

    1.69
    RXRX 30-day relative volume is 1.69

    ATR

    $0.43
    RXRX average true range is $0.43

    10-day Historical Volatility

    78.57%
    RXRX 10-day historical volatility is 78.57%

    Dividend

    Income Statement

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Revenue

    Revenue

    $58.49M
    RXRX annual revenue is $58.49 million

    Revenue Analysts estimate

    $70.98M
    RXRX annual revenue is currently -17.60% lower than the consensus analysts' forecast

    Revenue 1-year change

    +33.3%
    RXRX annual revenue is up +33.3% year-on-year

    Revenue Sector rank

    49.43%
    RXRX annual revenue is higher than 49.43% of companies in Healthcare sector

    EPS

    EPS

    -$1.69
    RXRX annual earnings per share is -$1.69

    EPS Analysts estimate

    -$1.46
    RXRX annual earnings per share is currently +16.01% higher than the consensus analysts' forecast

    EPS 1-year change

    -6.96%
    RXRX annual earnings per share is down -6.96% year-on-year

    EPS Sector rank

    42.09%
    RXRX annual earnings per share is higher than 42.09% of companies in Healthcare sector

    Profit

    Gross profit

    $13.25M
    RXRX annual gross profit is $13.25 million

    Gross margin

    22.65%
    RXRX annual gross profit margin is 22.65%

    Operating profit

    -$479.00M
    RXRX annual operating income is -$479.00 million

    Operating margin

    -818.98%
    RXRX annual operating profit margin is -818.98%

    Net income

    -$463.66M
    RXRX annual net profit is -$463.66 million

    Net margin

    -792.75%
    RXRX annual net profit margin is -792.75%

    Expenses

    Total expenses

    $537.49M
    RXRX annual total expenses is $537.49 million

    Operating expenses

    $492.25M
    RXRX annual total operating expenses is $492.25 million

    Cost of goods sold

    $45.24M
    RXRX annual cost of goods sold is $45.24 million

    Selling, general & administrative expenses

    $178.18M
    RXRX annual SGA is $178.18 million

    Depreciation and amortization

    $36.49M
    RXRX annual depreciation & amortization is $36.49 million

    Interest expense

    $1.57M
    RXRX annual interest expense is $1.57 million

    Income tax

    -$1.13M
    RXRX annual income tax is -$1.13 million

    EBIT & EBITDA

    EBIT

    -$463.22M
    RXRX annual earnings before interest & taxes is -$463.22 million

    EBITDA

    -$426.72M
    RXRX annual EBITDA is -$426.72 million

    Balance Sheet

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Assets

    Total assets

    $1.45B
    RXRX annual total assets is $1.45 billion

    Non current assets

    $734.33M
    RXRX annual long term assets is $734.33 million

    Current assets

    $714.27M
    RXRX annual total current assets is $714.27 million

    Cash and cash equivalents

    $594.35M
    RXRX annual cash & cash equivalents is $594.35 million

    Accounts receivable

    -
    RXRX annual accounts receivable value is unknown

    Inventory

    -
    RXRX annual inventory value is unknown

    Liabilities

    Total liabilities

    $413.82M
    RXRX annual total liabilities is $413.82 million

    Long term liabilities

    $226.34M
    RXRX annual total long term liabilities is $226.34 million

    Current liabilities

    $187.47M
    RXRX annual total current liabilities is $187.47 million

    Accounts payable

    $21.61M
    RXRX annual accounts payable is $21.61 million

    Debt

    Total debt

    $108.49M
    RXRX annual total debt is $108.49 million

    Total debt 1-year change

    +114.11%
    RXRX annual total debt is up +114.11% year-on-year

    Long term debt

    $86.27M
    RXRX annual long term debt is $86.27 million

    Short term debt

    $22.22M
    RXRX annual short term debt is $22.22 million

    Equity & Capital

    Shareholders equity

    $1.03B
    RXRX annual stockholders equity is $1.03 billion

    Book value

    $1.03B
    RXRX annual book value is $1.03 billion

    Retained earnings

    -$1.43B
    RXRX annual retained earnings is -$1.43 billion

    Working capital

    $526.80M
    RXRX annual working capital is $526.80 million

    Cash Flow Statement

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Cashflow Activities

    Cash from operations

    -$359.17M
    RXRX annual cash flow from operations is -$359.17 million

    Cash from operations 1-year change

    -24.81%
    RXRX annual cash flow from operations is down -24.81% year-on-year

    Cash from investing

    $260.06M
    RXRX annual cash flow from investing activities is $260.06 million

    Cash from investing 1-year change

    +2642.62%
    RXRX annual cash flow from investing activities is up +2642.62% year-on-year

    Cash from financing

    $304.12M
    RXRX annual cash flow from financing activities is $304.12 million

    Cash from financing 1-year change

    +117.02%
    RXRX annual cash flow from financing activities is up +117.02% year-on-year

    CAPEX

    CAPEX

    $17.05M
    RXRX annual capital expenditures is $17.05 million

    CAPEX 1-year change

    +35.8%
    RXRX annual capital expenditures is up +35.8% year-on-year

    Free Cash Flow

    Free cash flow

    -$376.22M
    RXRX annual free cash flow is -$376.22 million

    Free cash flow 1-year change

    -25.27%
    RXRX annual free cash flow is down -25.27% year-on-year

    Profitability Ratios

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Margins

    Gross margin

    22.65%
    RXRX annual gross profit margin is 22.65%

    Operating margin

    -818.98%
    RXRX annual operating profit margin is -818.98%

    Net margin

    -792.75%
    RXRX annual net profit margin is -792.75%

    ROA & ROE

    ROA

    -44.11%
    RXRX annual return on assets is -44.11%

    ROE

    -61.90%
    RXRX annual return on equity is -61.90%

    Valuation

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    PE Ratio

    PE ratio

    -
    RXRX price to earnings ratio value is unknown

    PE ratio Sector rank

    -
    RXRX price to earnings ratio is unknown

    PB Ratio

    PB ratio

    2.19
    RXRX price to book ratio is 2.19

    PB ratio Sector rank

    60.69%
    RXRX price to book ratio is higher than 60.69% of companies in Healthcare sector

    PS Ratio

    PS ratio

    34.18
    RXRX price to sales ratio is 34.18

    PS ratio Sector rank

    89.01%
    RXRX price to sales ratio is higher than 89.01% of companies in Healthcare sector

    Enterprise value

    Enterprise value

    $1.64B
    RXRX enterprise value is $1.64 billion

    Enterprise value Sector rank

    78.98%
    RXRX enterprise value is higher than 78.98% of companies in Healthcare sector

    EV/EBITDA

    EV/EBITDA

    -3.12
    RXRX EV/EBITDA is -3.12

    EV/EBITDA Sector rank

    30.37%
    RXRX EV/EBITDA is higher than 30.37% of companies in Healthcare sector

    Financial Health

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Liquidity

    Current ratio

    3.81
    RXRX annual current ratio is 3.81

    Quick ratio

    -
    RXRX annual quick ratio value is unknown

    Leverage

    Debt to equity

    0.03
    RXRX annual debt to equity ratio is 0.03

    Interest coverage ratio

    -294.67
    RXRX annual interest coverage ratio is -294.67

    Risk & Stability

    Piotroski F-Score

    1
    RXRX piotroski f-score is 1

    Altman Z-Score

    1.00
    RXRX altman z-score is 1.00

    Analyst ratings

    Recent major analysts updates

    Jun 16, 25 Morgan Stanley
    Equal-Weight
    May 6, 25 Needham
    Buy
    Apr 10, 25 Morgan Stanley
    Equal-Weight
    Apr 8, 25 Needham
    Buy
    Feb 28, 25 Leerink Partners
    Market Perform
    Feb 6, 25 Needham
    Buy
    Jan 8, 25 Keybanc
    Overweight
    Dec 11, 24 Needham
    Buy
    Nov 20, 24 Needham
    Buy
    Nov 7, 24 Needham
    Buy

    Institutional Ownership

    Screeners with RXRX included

    Growing Shares Outstanding
    Mid cap stocks
    US stocks
    Stocks with high beta
    Best performing stocks last month
    Stocks below SMA 200
    Stocks recommended to hold
    NASDAQ Dividend Calendar
    Stocks below analysts price target
    Healthcare sector
    • What is the ticker symbol for Recursion Pharmaceuticals?
    • Does Recursion Pharmaceuticals pay dividends?
    • What sector is Recursion Pharmaceuticals in?
    • What industry is Recursion Pharmaceuticals in?
    • What country is Recursion Pharmaceuticals based in?
    • When did Recursion Pharmaceuticals go public?
    • Is Recursion Pharmaceuticals in the S&P 500?
    • Is Recursion Pharmaceuticals in the NASDAQ 100?
    • Is Recursion Pharmaceuticals in the Dow Jones?
    • When was Recursion Pharmaceuticals's last earnings report?
    • When does Recursion Pharmaceuticals report earnings?
    • Should I buy Recursion Pharmaceuticals stock now?

    What is the ticker symbol for Recursion Pharmaceuticals?

    The ticker symbol for Recursion Pharmaceuticals is NASDAQ:RXRX

    Does Recursion Pharmaceuticals pay dividends?

    No, Recursion Pharmaceuticals does not pay dividends

    What sector is Recursion Pharmaceuticals in?

    Recursion Pharmaceuticals is in the Healthcare sector

    What industry is Recursion Pharmaceuticals in?

    Recursion Pharmaceuticals is in the Biotechnology industry

    What country is Recursion Pharmaceuticals based in?

    Recursion Pharmaceuticals is headquartered in United States

    When did Recursion Pharmaceuticals go public?

    Recursion Pharmaceuticals's initial public offering (IPO) was on April 16, 2021

    Is Recursion Pharmaceuticals in the S&P 500?

    No, Recursion Pharmaceuticals is not included in the S&P 500 index

    Is Recursion Pharmaceuticals in the NASDAQ 100?

    No, Recursion Pharmaceuticals is not included in the NASDAQ 100 index

    Is Recursion Pharmaceuticals in the Dow Jones?

    No, Recursion Pharmaceuticals is not included in the Dow Jones index

    When was Recursion Pharmaceuticals's last earnings report?

    Recursion Pharmaceuticals's most recent earnings report was on May 5, 2025

    When does Recursion Pharmaceuticals report earnings?

    The next expected earnings date for Recursion Pharmaceuticals is Aug 8, 2025

    Should I buy Recursion Pharmaceuticals stock now?

    As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
    On this page